Carl Casale, former CEO of Inver Grove Heights-based CHS Inc., now pursues his passion for agriculture as an investor.
A fourth-generation farmer, Casale seeks investment opportunities aligned with sustainable food production as senior agricultural partner with Ospraie Ag Science. Casale helped launch the venture arm of Ospraie Management a year ago after consulting on the New York-based firm's $75 million recapitalization of Marrone Bio Innovations, a California-based biopesticide company. Under Casale, Ospraie has raised $45 million for Vancouver-based Terramera, $4 million for Virginia-based AgroSpheres Inc. and $3 million for BeeFlow, an Argentine startup.
Casale left CHS in 2017 having doubled its balance sheet to $17.3 billion during his seven-year tenure.
Q: What are your portfolio companies working on?
A: Terramera has discovered basically potentiators or synergists that can make both biological pesticides and synthetic pesticides work at perhaps one-tenth the rate. There's an economic benefit in terms of lower resource consumption and reducing the impact on the environment. Agrospheres' concept is making biopesticides and synthetic pesticides more effective. If I can make a biopesticide last in the environment for seven days instead of two, I don't have to spray as often if I can do that through extended release or extended control. It's like time-release medicine. BeeFlow is a pollination enhancement company that basically provides customized nectar for bees to train them to pollinate certain crops more efficiently. They've done some trials on our farm.
Q: How do you evaluate potential investment opportunities?
A: We've developed a very narrow investment thesis. It's basically on agricultural production tools that fulfill that "do more with less" mission. At this stage you're really partnering, you're not just investing in the company. So how are the founders? How is the leadership? How self-aware are they? How amenable to coaching are they? How strong is the intellectual property? Can it be protected? We have the ability to be patient. We don't have a time duration exit on the money that we invest.
Q: How does investing in ag tech startups differ from being a Big Ag CEO?